After targeting and inhibiting the function of the MSTN gene in the CKD mice followed by subcutaneous administration of MSTN-ASO weekly for eight weeks (after application of a total of eight doses), our study revealed that subcutaneous administration of MSTN-ASO over eight weeks led to a restoration of muscle mass, strength, and function, as confirmed by the weight of skeletal muscles, treadmill test, and forelimb grip strength test, indicating functional recovery of the skeletal muscles. Here, MSTN is linked to chronic kidney disease.